First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. (Q53073357)
Jump to navigation
Jump to search
scientific article published on 5 September 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. |
scientific article published on 5 September 2010 |
Statements
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients (English)
I E Smith
J-Y Pierga
H Cortés-Funes
C Thomssen
A Fabi
B Xu
F A Franke
B Kaufman
P Mainwaring
B De Valk
J L González-Trujillo
I Koza
K Petrakova
D Pereira
K I Pritchard
ATHENA Study Group
5 September 2010
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference